Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

well-tolerated and may represent a benefit for patients in terms of convenience and ease of administration. Tanespimycin is clearly an active and manageable agent and is deserving of further clinical study."

"We continue to see meaningful antitumor activity and tolerability with the tanespimycin plus bortezomib combination in multiple myeloma across patient populations. In addition, we are observing intriguing evidence supporting the hypothesis that in the tanespimycin/bortezomib combination, tanespimycin may be exerting a neuroprotective effect based on the observation of reduced neuropathy, a side effect associated with bortezomib," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "The data from this ongoing trial are still being evaluated, and multiple patients remain on study. At this time, the overall response rate appears to be lower than previously reported. We are investigating whether there were patient characteristics that may have contributed to this lower response rate, including the possibility that patients added to the study since the data were last reported represented a more advanced and heavily pretreated population. We will complete the study and further evaluate the data in consultation with multiple myeloma experts to confirm the most expeditious course forward. Taken as a whole, the currently available data from this trial suggest that there may be utility in adjusting the TIME program to optimize the therapeutic potential of the tanespimycin and bortezomib combination. We have not, however, made any definitive decisions concerning a potential adjustment."

Tanespimycin Phase 1b Trial Results

The objective of the Phase 1b dose-escalating trial was to evaluate tanespimycin with bortezomib in patients with relapsed, refractory multiple myeloma, relative to safety, pharmacokinetic, pharmacodynamic and anti-myeloma effects. Dose escalations in the entire trial ranged from 100-340 mg/m2 for
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
(Date:9/30/2014)... 2014  HealthLoop® released an app version of its ... 8 and allows people to share medical device and ... iOS technologies to enhance the HealthLoop experience for iPhone ... their doctors between visits. "This new ... collect is exciting," says HealthLoop founder Dr. Jordan ...
(Date:9/30/2014)... 2014  Georgia-Pacific Professional is a leading provider ... a wide range of away from home applications. ... in healthcare, including hospitals, long-term care facilities, surgical ... its healthcare products and solutions to the dental ... of infection control in the dental office," said ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set ... Nashville, Tennessee. RMS welcomes the launch of an entirely ... of a new treatment center for the Lung Institute. ... Institute to Nashville, the hope is to bring awareness ... diagnosed and undiagnosed. With Nashville being a hub for ...
(Date:9/30/2014)... 30, 2014 Dr. Karl R.O.S. Johnson, ... program of care that is dramatically improving the ... clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, multi-dimensional approach ... also addresses sources of inflammation, neurology of the joint ... chain” from the brain to the spine, to the ...
(Date:9/30/2014)... Bifidobacteria, the primary bacteria found in the large ... so a high Bifido probiotic can help replenish this ... Men’s Complete contains 90 Billion live probiotic cultures, ... support a healthy large intestine (colon) where elimination occurs ... cultures from 7 Lactobacillus strains to help maintain a ...
(Date:9/30/2014)... 2014) Levothyroxine is considered the gold standard therapy ... review of therapies for the condition including combining ... assessment, say a team of investigators.,1Their analysis, published as ... , finds insufficient consistent data exist to recommend a ... sold under various trade names, such as Synthroid ...
(Date:9/30/2014)... Department of Defense (DoD) is being launched to ... may lead to the first successful treatments for ... athletes and soldiers, but also millions among the ... , Under the partnership, officially launched October 1, ... the DoD, the research team, representing many universities, ...
Breaking Medicine News(10 mins):Health News:Regenerative Medicine Solutions Expanding 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2Health News:US aims for traumatic brain injury clinical trial success 2Health News:US aims for traumatic brain injury clinical trial success 3Health News:US aims for traumatic brain injury clinical trial success 4
... Healthy Snacking, MINDEN, Nev., April 22 Nutrition ... Detour(R) bar, today announced,the introduction of a convenient new ... Bar(TM). The snack size bar is loaded with,essential nutrients ... a,healthy lifestyle. With seven grams of protein and just ...
... Fla., April 22 Applying the Family and Medical,Leave ... the country. A recent change and several proposed amendments ... and will clarify,application of the Act in both civilian ... employers must grant eligible,employees up to a total of ...
... BEHAVIORAL ... CARE SERVICES ACROSS NEW MEXICO, ALBUQUERQUE, N.M., April ... that serves the New Mexico,Behavioral Health Collaborative, announced it ... providers to further develop,community-based services across the state. This ...
... report from the American Cancer Society highlights that long-term ... been responsible for declining cancer death rates in the ... and Figures 2008 (CPED), points out that drops in ... rates have been stable or slightly declining since 2000 ...
... treatment with chemotherapeutic agents is often associated with ... referred to as chemobrain - that may compromise ... cancer survivors. Now, research published in the open ... a single chemotherapeutic agent, 5-fluorouracil (5-FU), by itself ...
... ,biological mechanism, that leads to adverse reactions identified, officials ... heparin products have now been found in at least ... ongoing surveillance measures to ensure the safety of the ... addition, officials said contaminated lots of the blood thinner ...
Cached Medicine News:Health News:Detour(R) Unveils Snack Size Protein Bar 2Health News:Changes to Family and Medical Leave Act Clarify Employer Responsibilities 2Health News:Changes to Family and Medical Leave Act Clarify Employer Responsibilities 3Health News:ValueOptions(R) New Mexico Provides $10.3 Million for Community Behavioral Health Care Organizations 2Health News:American Cancer Society report details cancer prevention efforts 2Health News:American Cancer Society report details cancer prevention efforts 3Health News:American Cancer Society report details cancer prevention efforts 4Health News:Chemotherapy causes delayed severe neural damage 2Health News:FDA: Contaminated Heparin Found in 10 Countries 2Health News:FDA: Contaminated Heparin Found in 10 Countries 3Health News:FDA: Contaminated Heparin Found in 10 Countries 4
...
... The Slim-LOC Plate is a ... intervertebral body fixation. The Slim-LOC is ... design, modified by current market technology. ... versatility & integrated instrumentation. Reduced width ...
... Osmium is a cervical plate system ... spine. The implant provides for the ... the bone transplant has consolidated. Optimized ... and bicortical fixation. Maximum purchase also ...
... meet the clinical challenges of anterior cervical ... and the choice of fixed angle screws ... for ease of implantation in complex cases. ... the surgeon the versatility of creating a ...
Medicine Products: